Brain Metastasis-Pipeline Review, H2 2015

Brain Metastasis-Pipeline Review, H2 2015

  • Products Id :- GMDHC6938IDB
  • |
  • Pages: 194
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Brain Metastasis-Pipeline Review, H2 2015


Global Markets Direct's, 'Brain metastasis-Pipeline Review, H2 2015', provides an overview of the Brain metastasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain metastasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Brain metastasis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Brain metastasis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Brain metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Brain metastasis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Brain metastasis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Brain metastasis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Brain Metastasis Overview 10

Therapeutics Development 11

Pipeline Products for Brain Metastasis-Overview 11

Pipeline Products for Brain Metastasis-Comparative Analysis 12

Brain Metastasis-Therapeutics under Development by Companies 13

Brain Metastasis-Therapeutics under Investigation by Universities/Institutes 15

Brain Metastasis-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Brain Metastasis-Products under Development by Companies 19

Brain Metastasis-Products under Investigation by Universities/Institutes 21

Brain Metastasis-Companies Involved in Therapeutics Development 22

AbbVie Inc. 22

AngioChem Inc. 23

BBB Therapeutics B.V. 24

biOasis Technologies Inc. 25

Bristol-Myers Squibb Company 26

Diffusion Pharmaceuticals LLC 27

e-Therapeutics Plc 28

Exelixis, Inc. 29

GlaxoSmithKline Plc 30

Hutchison MediPharma Limited 31

Komipharm International Co., Ltd. 32

Nektar Therapeutics 33

Nerviano Medical Sciences S.r.l. 34

Novartis AG 35

Oncothyreon Inc. 36

Pfizer Inc. 37

Philogen S.p.A. 38

Phosplatin Therapeutics LLC 39

Puma Biotechnology, Inc. 40

Radius Health, Inc. 41

Sanofi 42

Spectrum Pharmaceuticals, Inc. 43

Tocagen Inc. 44

Brain Metastasis-Therapeutics Assessment 45

Assessment by Monotherapy Products 45

Assessment by Combination Products 46

Assessment by Target 47

Assessment by Mechanism of Action 50

Assessment by Route of Administration 53

Assessment by Molecule Type 55

Drug Profiles 57

dabrafenib mesylate + trametinib dimethyl sulfoxide-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

2B3-101-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

ANG-1005-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

ANG-4043-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

BT-2111-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

cabazitaxel-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

cabozantinib s-malate-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

ceritinib-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

dacomitinib-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

etirinotecan pegol-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

ETS-2101-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

HMPL-813-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

ipilimumab-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

irbinitinib-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

KML-001-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

lucanthone hydrochloride-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

MDNA-55-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

neratinib-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

nimotuzumab-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

NMSE-973-Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

PB-357-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

PF-06463922-Drug Profile 103

Product Description 103

Mechanism of Action 103

R&D Progress 103

plinabulin-Drug Profile 105

Product Description 105

Mechanism of Action 105

R&D Progress 105

PT-112-Drug Profile 107

Product Description 107

Mechanism of Action 107

R&D Progress 107

RAD-1901-Drug Profile 108

Product Description 108

Mechanism of Action 108

R&D Progress 108

radretumab-Drug Profile 110

Product Description 110

Mechanism of Action 110

R&D Progress 110

RRX-001-Drug Profile 112

Product Description 112

Mechanism of Action 112

R&D Progress 112

TPI-287-Drug Profile 114

Product Description 114

Mechanism of Action 114

R&D Progress 114

transcrocetinate sodium-Drug Profile 116

Product Description 116

Mechanism of Action 116

R&D Progress 116

Vaccine for Metastatic Brain Tumor-Drug Profile 117

Product Description 117

Mechanism of Action 117

R&D Progress 117

veliparib-Drug Profile 118

Product Description 118

Mechanism of Action 118

R&D Progress 118

vocimagene amiretrorepvec + flucytosine ER-Drug Profile 121

Product Description 121

Mechanism of Action 121

R&D Progress 121

X-82-Drug Profile 123

Product Description 123

Mechanism of Action 123

R&D Progress 123

Brain Metastasis-Recent Pipeline Updates 125

Brain Metastasis-Dormant Projects 183

Brain Metastasis-Discontinued Products 184

Brain Metastasis-Product Development Milestones 185

Featured News & Press Releases 185

Aug 28, 2014: Radius Health Reports Proof of Mechanism for RAD1901 and Presentation at 4th Annual Brain Metastases Research and Emerging Therapy Conference in September 185

Nov 12, 2013: Study Demonstrates biOasis Technologies' Conjugate of Metastatic Cancer Drug, Herceptin, Penetrates Blood-Tumor Barrier 10 Times Greater Than Herceptin Alone 186

Oct 08, 2013: Angiochem to Present at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 187

Jul 29, 2013: Nerviano Medical Sciences researchers report data on a novel molecule inhibitor of HSP90 187

Apr 09, 2013: biOasis Provides Update On BT2111-Herceptin Program 187

Dec 03, 2012: Geron Discontinues Development Of Brain Cancer Drug Candidate GRN1005 188

Dec 22, 2011: Geron Initiates Phase II Trial Of GRN1005 In Brain Metastases Arising From Lung Cancer 188

Nov 15, 2011: Geron Presents Final Phase I Clinical Data On GRN1005 At AACR-NCI-EORTC 189

Jun 07, 2010: Angiochem Presents Complete Phase I/II Clinical Data Of ANG1005 For Treatment Of Brain Metastases 191

Appendix 193

Methodology 193

Coverage 193

Secondary Research 193

Primary Research 193

Expert Panel Validation 193

Contact Us 193

Disclaimer 194

List of Tables

Number of Products under Development for Brain Metastasis, H2 2015 11

Number of Products under Development for Brain Metastasis-Comparative Analysis, H2 2015 12

Number of Products under Development by Companies, H2 2015 14

Number of Products under Investigation by Universities/Institutes, H2 2015 15

Comparative Analysis by Late Stage Development, H2 2015 16

Comparative Analysis by Clinical Stage Development, H2 2015 17

Comparative Analysis by Early Stage Development, H2 2015 18

Products under Development by Companies, H2 2015 19

Products under Development by Companies, H2 2015 (Contd..1) 20

Products under Investigation by Universities/Institutes, H2 2015 21

Brain Metastasis-Pipeline by AbbVie Inc., H2 2015 22

Brain Metastasis-Pipeline by AngioChem Inc., H2 2015 23

Brain Metastasis-Pipeline by BBB Therapeutics B.V., H2 2015 24

Brain Metastasis-Pipeline by biOasis Technologies Inc., H2 2015 25

Brain Metastasis-Pipeline by Bristol-Myers Squibb Company, H2 2015 26

Brain Metastasis-Pipeline by Diffusion Pharmaceuticals LLC, H2 2015 27

Brain Metastasis-Pipeline by e-Therapeutics Plc, H2 2015 28

Brain Metastasis-Pipeline by Exelixis, Inc., H2 2015 29

Brain Metastasis-Pipeline by GlaxoSmithKline Plc, H2 2015 30

Brain Metastasis-Pipeline by Hutchison MediPharma Limited, H2 2015 31

Brain Metastasis-Pipeline by Komipharm International Co., Ltd., H2 2015 32

Brain Metastasis-Pipeline by Nektar Therapeutics, H2 2015 33

Brain Metastasis-Pipeline by Nerviano Medical Sciences S.r.l., H2 2015 34

Brain Metastasis-Pipeline by Novartis AG, H2 2015 35

Brain Metastasis-Pipeline by Oncothyreon Inc., H2 2015 36

Brain Metastasis-Pipeline by Pfizer Inc., H2 2015 37

Brain Metastasis-Pipeline by Philogen S.p.A., H2 2015 38

Brain Metastasis-Pipeline by Phosplatin Therapeutics LLC, H2 2015 39

Brain Metastasis-Pipeline by Puma Biotechnology, Inc., H2 2015 40

Brain Metastasis-Pipeline by Radius Health, Inc., H2 2015 41

Brain Metastasis-Pipeline by Sanofi, H2 2015 42

Brain Metastasis-Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015 43

Brain Metastasis-Pipeline by Tocagen Inc., H2 2015 44

Assessment by Monotherapy Products, H2 2015 45

Assessment by Combination Products, H2 2015 46

Number of Products by Stage and Target, H2 2015 48

Number of Products by Stage and Mechanism of Action, H2 2015 51

Number of Products by Stage and Route of Administration, H2 2015 54

Number of Products by Stage and Molecule Type, H2 2015 56

Brain Metastasis Therapeutics-Recent Pipeline Updates, H2 2015 125

Brain Metastasis-Dormant Projects, H2 2015 183

Brain Metastasis-Discontinued Products, H2 2015 184

List of Figures

Number of Products under Development for Brain Metastasis, H2 2015 11

Number of Products under Development for Brain Metastasis-Comparative Analysis, H2 2015 12

Number of Products under Development by Companies, H2 2015 13

Comparative Analysis by Clinical Stage Development, H2 2015 17

Comparative Analysis by Early Stage Products, H2 2015 18

Assessment by Monotherapy Products, H2 2015 45

Assessment by Combination Products, H2 2015 46

Number of Products by Top 10 Targets, H2 2015 47

Number of Products by Stage and Top 10 Targets, H2 2015 47

Number of Products by Top 10 Mechanism of Actions, H2 2015 50

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 50

Number of Products by Top 10 Routes of Administration, H2 2015 53

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 53

Number of Products by Top 10 Molecule Types, H2 2015 55

Number of Products by Stage and Top 10 Molecule Types, H2 2015 55

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

AbbVie Inc.

AngioChem Inc.

BBB Therapeutics B.V.

biOasis Technologies Inc.

Bristol-Myers Squibb Company

Diffusion Pharmaceuticals LLC

e-Therapeutics Plc

Exelixis, Inc.

GlaxoSmithKline Plc

Hutchison MediPharma Limited

Komipharm International Co., Ltd.

Nektar Therapeutics

Nerviano Medical Sciences S.r.l.

Novartis AG

Oncothyreon Inc.

Pfizer Inc.

Philogen S.p.A.

Phosplatin Therapeutics LLC

Puma Biotechnology, Inc.

Radius Health, Inc.


Spectrum Pharmaceuticals, Inc.

Tocagen Inc.

Brain metastasis Therapeutic Products under Development, Key Players in Brain metastasis Therapeutics, Brain metastasis Pipeline Overview, Brain metastasis Pipeline, Brain metastasis Pipeline Assessment

select a license

Single User License
USD 2000 INR 136600
Site License
USD 4000 INR 273200
Corporate User License
USD 6000 INR 409800



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]